Statera Biopharma (STAB) 10-Q 14 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	Apr. 30, 2021
Document Information [Line Items]
Entity Registrant Name	CLEVELAND BIOLABS INC
Entity Central Index Key	0001318641
Trading Symbol	cbli
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		15,468,945
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common stock, par value $0.005 per share

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 14,359,297	$ 1,946,418
Short-term investments	264,193	324,870
Accounts receivable		11,512
Other current assets	70,120	31,506
Total current assets	14,693,610	2,314,306
Equipment, net	6,148	3,715
Total assets	14,699,758	2,318,021
Current liabilities:
Accounts payable	309,721	167,773
Accrued expenses	208,430	136,838
Total liabilities	518,151	304,611
Stockholders’ equity:
Preferred stock, $.005 par value; 1,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 0 shares issued and outstanding as of March 31, 2021 and December 31, 2020
Common stock, $.005 par value; 25,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 15,468,945 and 13,376,062 shares issued and outstanding as of March 31, 2021 and December 31, 2020	77,340	66,876
Additional paid-in capital	179,475,388	166,762,778
Accumulated other comprehensive loss	(690,864)	(685,680)
Accumulated deficit	(169,642,127)	(169,104,029)
Total Cleveland BioLabs, Inc. stockholders’ equity (deficit)	9,219,737	(2,960,055)
Noncontrolling interest in stockholders’ equity	4,961,870	4,973,465
Total stockholders’ equity	14,181,607	2,013,410
Total liabilities and stockholders’ equity	$ 14,699,758	$ 2,318,021

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Preferred stock, par value (in dollars per share)	$ 0.005	$ 0.005
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.005	$ 0.005
Common stock, shares authorized (in shares)	25,000,000	25,000,000
Common stock, shares issued (in shares)	15,468,945	13,376,062
Common stock, shares outstanding (in shares)	15,468,945	13,376,062

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues:
Grants and contracts		$ 156,042
Operating expenses:
Research and development	118,258	218,208
General and administrative	433,004	382,166
Total operating expenses	551,262	600,374
Loss from operations	(551,262)	(444,332)
Other income (expense):
Interest and other income	3,915	2,900
Foreign exchange gain	142	393
Change in value of warrant liability		(160,689)
Total other income (expense)	4,057	(157,396)
Net loss	(547,205)	(601,728)
Net loss attributable to noncontrolling interests	9,107	13,196
Net loss attributable to Cleveland BioLabs, Inc.	$ (538,098)	$ (588,532)
Net loss attributable to common stockholders per share of common stock, basic and diluted (in dollars per share)	$ (0.04)	$ (0.05)
Weighted average number of shares used in calculating net loss per share, basic and diluted (in shares)	14,227,014	11,353,456

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net loss including noncontrolling interests	$ (547,205)	$ (601,728)
Other comprehensive loss:
Foreign currency translation adjustment	(7,672)	(108,100)
Comprehensive loss including noncontrolling interests	(554,877)	(709,828)
Comprehensive loss attributable to noncontrolling interests	11,595	46,819
Comprehensive loss attributable to Cleveland BioLabs, Inc.	$ (543,282)	$ (663,009)

Consolidated Condensed Statem_3

Consolidated Condensed Statement of Stockholders' Equity (Unaudited) - USD ($)	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Total
Balance (in shares) at Dec. 31, 2019				11,298,239
Beginning balance at Dec. 31, 2019	$ (568,030)	$ (166,705,572)	$ 5,039,878	$ 56,487		$ 163,161,523	$ 984,286
Exercise of warrants (in shares)				105,000
Exercise of warrants				$ 53		504,853	504,906
Net loss		(588,532)	(13,196)				(601,728)
Foreign currency translation	(74,777)		(33,623)				(108,100)
Balance (in shares) at Mar. 31, 2020				11,403,239
Ending balance at Mar. 31, 2020	(642,807)	(167,294,104)	4,993,059	$ 56,540		163,666,376	779,364
Balance (in shares) at Dec. 31, 2020				13,376,062
Beginning balance at Dec. 31, 2020	(685,680)	(169,104,029)	4,973,465	$ 66,876		166,762,778	2,013,410
Exercise of warrants (in shares)				92,883
Exercise of warrants				$ 464		(464)
Net loss		(538,098)	(9,107)				(547,205)
Foreign currency translation	(5,184)		(2,488)				(7,672)
Issuance of common stock, net of offering costs (in shares)				2,000,000
Issuance of common stock, net of offering costs				$ 10,000		12,713,074	12,723,074
Balance (in shares) at Mar. 31, 2021				15,468,945
Ending balance at Mar. 31, 2021	$ (690,864)	$ (169,642,127)	$ 4,961,870	$ 77,340		$ 179,475,388	$ 14,181,607

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (547,205)	$ (601,728)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,883	3,080
Change in value of warrant liability		160,689
Changes in operating assets and liabilities:
Accounts receivable and other current assets	(27,227)	8,074
Accounts payable and accrued expenses	209,456	4,292
Net cash used in operating activities	(363,093)	(425,593)
Cash flows from investing activities:
Sale of short-term investments	53,807
Net cash provided by investing activities	53,807
Cash flows from financing activities:
Issuance of common stock, net of offering costs	12,723,074
Exercise of warrants		382,215
Net cash provided by financing activities	12,723,074	382,215
Effect of exchange rate change on cash and equivalents	(909)	(23,935)
Increase (decrease) in cash and cash equivalents	12,412,879	(67,313)
Cash and cash equivalents at beginning of period	1,946,418	1,126,124
Cash and cash equivalents at end of period	$ 14,359,297	$ 1,058,811

Note 1 - Description of Busines

Note 1 - Description of Business	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Cleveland BioLabs, Inc. (" CBLI Company TLR CBLI was incorporated in Delaware in June 2003 U.S. Russia two one 612, BioLab 612 2012 November 2020; Panacela RUSNANO 2011. In addition, the Company has an investment in Genome Protection, Inc. (" GPI not 50% March 31, 2021 no On October 16, 2020, Merger Sub Cytocom Merger Agreement Merger not, December 31, 2020, 57% 57% 43% seven three four 4 1933, not not 4 February 16, 2021 May 7, 2021 not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Basis of Presentation and Consolidation The accompanying unaudited consolidated condensed financial statements include the accounts of CBLI, BioLab 612, The consolidated condensed balance sheet as of December 31, 2020 GAAP 10 8 X SEC 10 December 31, 2020 2020 Form 10 In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to fairly present the financial position of the Company as of March 31, 2021 three March 31, 2021 2020 three March 31, 2021 2020 not may At March 31, 2021 $14.6 one no not Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (" FASB not not Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Short-Term Investments The Company's short-term investments are classified as held to maturity and are recorded at amortized cost. Short-term investments consisted of $0.3 three one Significant Customers and Accounts Receivable The following table presents our revenue by customer, on a proportional basis, for the three March 31, 2021 2020 Three Months Ended March 31, Customer 2021 2020 Variance Department of Defense 0.0 % 73.7 % (73.7 )% Incuron 0.0 % 26.3 % (26.3 )% Total 0.0 % 100.0 % (100 )% Other Comprehensive Income (Loss) The Company applies the Accounting Standards Codification (" Codification three March 31, 2021 Gains and losses on foreign exchange translations Beginning balance $ (685,680 ) Other comprehensive income (loss) before reclassifications (5,184 ) Amounts reclassified from accumulated other comprehensive loss — Ending balance $ (690,864 ) Accounting for Stock-Based Compensation The Cleveland Biolabs, Inc. Equity Incentive Plan, adopted in 2018 Plan March 31, 2021 597,557 523,656 67,901 2018 100,000 no 10 The 2013 ESPP may March 31, 2021 825,000 January 1 10% December 31st 100,000 15% 85% The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted where the vesting period is based on length of service or performance, while a Monte Carlo simulation model is used for estimating the fair value of stock options with market-based vesting conditions. No three March 31, 2021 March 31, 2020 Income Taxes No three March 31, 2021 2020 not 2021 not 2020 At March 31, 2021 $148.0 million, of which $139.7 not 2023, $8.3 no $4.3 not 2024. $93.8 not 2027, $0.3 not 2022. 6,459,948 July 9, 2015 60.2% 382 $124.8 $3.65 $73.4 $0.3 July 9, 2015, Earnings (Loss) per Share Basic net loss per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net loss by the weighted average number of shares outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive. The Company has excluded the following securities from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented. Additionally, there were no March 31, 2021 As of March 31, Common Equivalent Securities 2021 2020 Warrants 299,519 222,253 Options 67,901 96,397 Total 367,420 318,650 Contingencies From time to time, the Company may

Note 3 - Fair Value of Financia

Note 3 - Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. The Company measures and records warrant liabilities at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three • Level 1 • Level 2 • Level 3 no Cash equivalents include United States Treasury Notes with original maturities of three three The valuation methodologies used to measure the fair value of the Company's assets and instruments classified in stockholders' equity are described as follows: Certificates of deposit are carried at amortized cost, which approximates fair value and are included within short-term investments as a Level 2 The following tables represent the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis. As of March 31, 2021 Level 1 Level 2 Level 3 Total Assets: Short-term investments $ — $ 264,193 $ — $ 264,193 Total assets $ — $ 264,193 $ — $ 264,193 As of December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Short-term investments $ — $ 324,870 $ — $ 324,870 Total assets $ — $ 324,870 $ — $ 324,870 Accrued warrant liability $ — $ — $ — $ — The following table sets forth a summary of changes in the fair value of the Company's Level 3 Three Months Ended Three Months Ended March 31, 2021 March 31, 2020 Accrued Warrant Liability Accrued Warrant Liability Beginning Balance $ - $ 6,414 Total (gains) or losses, realized and unrealized, included in earnings (1) - 160,689 Settlements - (122,691 ) Ending Balance $ - $ 44,412 ( 1 Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. There were no three March 31, 2021 2020 As of March 31, 2021 December 31, 2020 no The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, approximate their fair values due to their short maturities.

Note 4 - Stockholders' Equity

Note 4 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	4. On February 19, 2021, Purchase Agreement 2,000,000 Shares $7.00 February 23, 2021. $14 Wainwright 150,000 Placement Agent Warrants $8.75 five The Company has granted options to purchase shares of common stock. The following is a summary of option award activity during the three March 31, 2021 Total Stock Options Outstanding Weighted Average Exercise Price per Share December 31, 2020 76,064 $ 27.35 Granted — — Vested — — Forfeited, Canceled (8,163 ) 143.62 March 31, 2021 67,901 $ 13.37 The following is a summary of outstanding stock options as of March 31, 2021 As of March 31, 2021 Stock Options Outstanding Vested Stock Options Quantity 67,901 67,901 Weighted Average Exercise Price $ 13.37 $ 13.37 Weighted Average Remaining Contractual Term (in Years) 3.36 3.36 Intrinsic Value $ 86,400 $ 86,400 For the three March 31, 2021 2020 no March 31, 2021 2020 $0 As of March 31, 2021 no not

Note 5 - Warrants

Note 5 - Warrants	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	5. In connection with previous sales of the Company's common stock and the issuance of debt instruments, warrants were issued which presently have exercise prices ranging from $2.03 $8.75. one seven The following table summarizes the activity in our outstanding warrants since December 31, 2020 Number of Warrants Weighted Average Exercise Price December 31, 2020 371,340 $ 7.28 Granted 150,000 8.75 Exercised (119,361 ) 2.03 Forfeited, Canceled (102,460 ) 20.40 March 31, 2021 299,519 $ 5.62

Note 6 - Significant Alliances

Note 6 - Significant Alliances and Related Parties	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	6. Roswell Park Cancer Institute The Company has entered into several agreements with Roswell Park Cancer Institute (" RPCI 1 1 CBL0137 Curaxin $0 $1,197 three March 31, 2021 2020, The Cleveland Clinic CBLI has entered into an exclusive license agreement with The Cleveland Clinic pursuant to which CBLI was granted an exclusive license to The Cleveland Clinic's research base underlying our therapeutic platform and certain product candidates licensed to Panacela. CBLI has the primary responsibility to fund all newly developed patents. However, The Cleveland Clinic retains ownership of those patents covered by the agreement. CBLI also agreed to use commercially diligent efforts to bring one August 6, 2018, no three March 31, 2021 2020 no three March 31, 2021 2020 Buffalo BioLabs and Incuron Our CSO, Dr. Andrei Gudkov, has business relationships with Buffalo BioLabs, LLC (" BBL no three March 31, 2021 2020. no three March 31, 2021 March 31, 2020 $0 $6,285, $0 $6,285 March 31, 2021 2020 Dr. Gudkov is also an uncompensated member of the board of directors for Incuron. Pursuant to master service and development agreements we have with Incuron, the Company performs various research, business development, clinical advisory, and management services for Incuron. The Company recognized revenue of $0 $41,010 three March 31, 2021 2020, no three March 31, 2021 2020, $130,000 $140,595, $0 $140,595 March 31, 2021 2020 Genome Protection GPI incurred $13,440 $13,440 three March 31, 2021 2020, no three March 31, 2021 2020.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Consolidation The accompanying unaudited consolidated condensed financial statements include the accounts of CBLI, BioLab 612, The consolidated condensed balance sheet as of December 31, 2020 GAAP 10 8 X SEC 10 December 31, 2020 2020 Form 10 In the opinion of the Company's management, any adjustments contained in the accompanying unaudited consolidated financial statements are of a normal recurring nature, and are necessary to fairly present the financial position of the Company as of March 31, 2021 three March 31, 2021 2020 three March 31, 2021 2020 not may At March 31, 2021 $14.6 one no not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (" FASB not not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Marketable Securities, Policy [Policy Text Block]	Short-Term Investments The Company's short-term investments are classified as held to maturity and are recorded at amortized cost. Short-term investments consisted of $0.3 three one
Receivable [Policy Text Block]	Significant Customers and Accounts Receivable The following table presents our revenue by customer, on a proportional basis, for the three March 31, 2021 2020 Three Months Ended March 31, Customer 2021 2020 Variance Department of Defense 0.0 % 73.7 % (73.7 )% Incuron 0.0 % 26.3 % (26.3 )% Total 0.0 % 100.0 % (100 )%
Comprehensive Income, Policy [Policy Text Block]	Other Comprehensive Income (Loss) The Company applies the Accounting Standards Codification (" Codification three March 31, 2021 Gains and losses on foreign exchange translations Beginning balance $ (685,680 ) Other comprehensive income (loss) before reclassifications (5,184 ) Amounts reclassified from accumulated other comprehensive loss — Ending balance $ (690,864 )
Share-based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation The Cleveland Biolabs, Inc. Equity Incentive Plan, adopted in 2018 Plan March 31, 2021 597,557 523,656 67,901 2018 100,000 no 10 The 2013 ESPP may March 31, 2021 825,000 January 1 10% December 31st 100,000 15% 85% The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted where the vesting period is based on length of service or performance, while a Monte Carlo simulation model is used for estimating the fair value of stock options with market-based vesting conditions. No three March 31, 2021 March 31, 2020
Income Tax, Policy [Policy Text Block]	Income Taxes No three March 31, 2021 2020 not 2021 not 2020 At March 31, 2021 $148.0 million, of which $139.7 not 2023, $8.3 no $4.3 not 2024. $93.8 not 2027, $0.3 not 2022. 6,459,948 July 9, 2015 60.2% 382 $124.8 $3.65 $73.4 $0.3 July 9, 2015,
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) per Share Basic net loss per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net loss by the weighted average number of shares outstanding for the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. Diluted net loss per share is identical to basic net loss per share as potentially dilutive securities have been excluded from the calculation of diluted net loss per common share because the inclusion of such securities would be antidilutive. The Company has excluded the following securities from the calculation of diluted net loss per share because all such securities were antidilutive for the periods presented. Additionally, there were no March 31, 2021 As of March 31, Common Equivalent Securities 2021 2020 Warrants 299,519 222,253 Options 67,901 96,397 Total 367,420 318,650
Commitments and Contingencies, Policy [Policy Text Block]	Contingencies From time to time, the Company may

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]	Three Months Ended March 31, Customer 2021 2020 Variance Department of Defense 0.0 % 73.7 % (73.7 )% Incuron 0.0 % 26.3 % (26.3 )% Total 0.0 % 100.0 % (100 )%
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Gains and losses on foreign exchange translations Beginning balance $ (685,680 ) Other comprehensive income (loss) before reclassifications (5,184 ) Amounts reclassified from accumulated other comprehensive loss — Ending balance $ (690,864 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of March 31, Common Equivalent Securities 2021 2020 Warrants 299,519 222,253 Options 67,901 96,397 Total 367,420 318,650

Note 3 - Fair Value of Financ_2

Note 3 - Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Fair Value, by Balance Sheet Grouping [Table Text Block]	As of March 31, 2021 Level 1 Level 2 Level 3 Total Assets: Short-term investments $ — $ 264,193 $ — $ 264,193 Total assets $ — $ 264,193 $ — $ 264,193 As of December 31, 2020 Level 1 Level 2 Level 3 Total Assets: Short-term investments $ — $ 324,870 $ — $ 324,870 Total assets $ — $ 324,870 $ — $ 324,870 Accrued warrant liability $ — $ — $ — $ —
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three Months Ended Three Months Ended March 31, 2021 March 31, 2020 Accrued Warrant Liability Accrued Warrant Liability Beginning Balance $ - $ 6,414 Total (gains) or losses, realized and unrealized, included in earnings (1) - 160,689 Settlements - (122,691 ) Ending Balance $ - $ 44,412

Note 4 - Stockholders' Equity (

Note 4 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Total Stock Options Outstanding Weighted Average Exercise Price per Share December 31, 2020 76,064 $ 27.35 Granted — — Vested — — Forfeited, Canceled (8,163 ) 143.62 March 31, 2021 67,901 $ 13.37
Share-based Compensation Arrangements by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	As of March 31, 2021 Stock Options Outstanding Vested Stock Options Quantity 67,901 67,901 Weighted Average Exercise Price $ 13.37 $ 13.37 Weighted Average Remaining Contractual Term (in Years) 3.36 3.36 Intrinsic Value $ 86,400 $ 86,400

Note 5 - Warrants (Tables)

Note 5 - Warrants (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Outstanding Warrants [Table Text Block]	Number of Warrants Weighted Average Exercise Price December 31, 2020 371,340 $ 7.28 Granted 150,000 8.75 Exercised (119,361 ) 2.03 Forfeited, Canceled (102,460 ) 20.40 March 31, 2021 299,519 $ 5.62

Note 1 - Description of Busin_2

Note 1 - Description of Business (Details Textual)	3 Months Ended
	Mar. 31, 2021
Number of Subsidiaries	2
Merger Sub [Member]
Business Acquisition, Percentage of Voting Interests Acquired	43.00%
Merger Sub [Member] | Cytocom [Member]
Business Acquisition, Percentage of Voting Interests Acquired	57.00%
BioLab 612 [Member]
Number of Wholly Owned Subsidiaries	1
GPI [Member]
Equity Method Investment, Ownership Percentage	50.00%

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Jul. 09, 2015	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Cash, Cash Equivalents, and Short-term Investments, Total		$ 14,600,000
Short-term Investments, Total		$ 264,193		$ 324,870
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		0	0
Income Tax Expense (Benefit), Total		$ 0	$ 0
Sale of Stock, Number of Shares Issued in Transaction (in shares)	6,459,948
Percentage of Common Shares Owned by Investor	60.20%
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total		148,000,000
Operating Loss Carryforwards, Amount Subject to Expiration		139,700,000
Operating Loss Carryforwards, Amount Not Subject to Expiration		8,300,000
Tax Credit Carryforward, Amount		4,300,000
Operating Loss Carryforwards With Limited Ability to Utilize		124,800,000
Tax Credit Carryforwards With Limited Ability to Utilize		3,650,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total		93,800,000
Tax Credit Carryforward, Amount		300,000
Operating Loss Carryforwards With Limited Ability to Utilize		73,400,000
Tax Credit Carryforwards With Limited Ability to Utilize		$ 300,000
The Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)		597,557
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)		523,656
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		67,901
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in shares)		100,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years
The ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)		825,000
Percentage of Common Stock Outstanding of Preceding Year		10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Limited Per Year (in shares)		100,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate		15.00%
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date		85.00%
Certificates of Deposit [Member]
Short-term Investments, Total		$ 300,000

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Customers and Accounts Receivable (Details)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Percentage of revenue	0.00%	100.00%
Variance	(100.00%)
Department of Defense [Member]
Percentage of revenue	0.00%	73.70%
Variance	(73.70%)
Incuron [Member]
Percentage of revenue	0.00%	26.30%
Variance	(26.30%)

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Other Comprehensive Income (Loss) (Details)	3 Months Ended
	Mar. 31, 2021USD ($)
Beginning balance	$ 2,013,410
Ending balance	14,181,607
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Beginning balance	(685,680)
Other comprehensive income (loss) before reclassifications	(5,184)
Amounts reclassified from accumulated other comprehensive loss
Ending balance	$ (690,864)

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive securities (in shares)	367,420	318,650
Warrant [Member]
Antidilutive securities (in shares)	299,519	222,253
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	67,901	96,397

Note 3 - Fair Value of Financ_3

Note 3 - Fair Value of Financial Instruments (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Assets, Fair Value Disclosure	$ 264,193		$ 324,870
Fair Value, Nonrecurring [Member]
Fair Value Measurement with Unobservable Inputs, Liability, Realized Gain (Loss)	0	$ 0
Assets, Fair Value Disclosure	0	0
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 0	$ 0

Note 3 - Fair Value of Financ_4

Note 3 - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Short-term investments	$ 264,193	$ 324,870
Total assets	264,193	324,870
Accrued warrant liability
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Short-term investments
Total assets
Accrued warrant liability
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Short-term investments	264,193	324,870
Total assets	264,193	324,870
Accrued warrant liability
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Short-term investments
Total assets
Accrued warrant liability

Note 3 - Fair Value of Financ_5

Note 3 - Fair Value of Financial Instruments - Changes in Fair Value of Level 3 Fair Value Measurements (Details) - Accrued Warrant Liability [Member] - USD ($)		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Beginning Balance			$ 6,414
Total (gains) or losses, realized and unrealized, included in earnings	[1]		160,689
Settlements			(122,691)
Ending Balance			$ 44,412
[1]	Unrealized gains or losses related to the accrued warrant liability were included as change in value of accrued warrant liability. There were no realized gains or losses for the three months ended March 31, 2021 and 2020.

Note 4 - Stockholders' Equity_2

Note 4 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Feb. 23, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 5.62		$ 7.28
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 0
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	150,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 8.75
Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)	2,000,000
Shares Issued, Price Per Share (in dollars per share)	$ 7
Proceeds from Issuance of Common Stock	$ 14,000

Note 4 - Stockholders' Equity -

Note 4 - Stockholders' Equity - Option Activity (Details) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Outstanding (in shares)	76,064
Outstanding, weighted average exercise price (in dollars per share)	$ 27.35
Granted (in shares)	0	0
Granted, weighted average exercise price (in dollars per share)
Vested (in shares)
Vested, weighted average exercise price (in dollars per share)
Forfeited, canceled (in shares)	(8,163)
Forfeited, canceled, weighted average exercise price (in dollars per share)	$ 143.62
Outstanding (in shares)	67,901
Outstanding, weighted average exercise price (in dollars per share)	$ 13.37

Note 4 - Stockholders' Equity_3

Note 4 - Stockholders' Equity - Summary of Outstanding Options (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Quantity, outstanding (in shares)	67,901	76,064
Quantity, vested (in shares)	67,901
Weighted-average exercise price, outstanding (in dollars per share)	$ 13.37	$ 27.35
Weighted-average exercise price, vested (in dollars per share)	$ 13.37
Weighted average remaining contractual term, outstanding (Year)	3 years 131 days
Weighted average remaining contractual term , vested (Year)	3 years 131 days
Intrinsic value, outstanding	$ 86,400
Intrinsic value, vested	$ 86,400

Note 5 - Warrants (Details Text

Note 5 - Warrants (Details Textual) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 5.62	$ 7.28
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2.03
Warrants and Rights Outstanding, Term (Year)	1 year
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 8.75
Warrants and Rights Outstanding, Term (Year)	7 years

Note 5 - Warrants - Outstanding

Note 5 - Warrants - Outstanding Warrants (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Warrants outstanding (in shares) | shares	371,340
Warrants outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 7.28
Warrants granted (in shares) | shares	150,000
Warrants granted, weighted average exercise price (in dollars per share) | $ / shares	$ 8.75
Warrants exercised (in shares) | shares	(119,361)
Warrants exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 2.03
Warrants forfeited, canceled (in shares) | shares	(102,460)
Warrants forfeited, canceled, weighted average exercise price (in dollars per share) | $ / shares	$ 20.40
Warrants outstanding (in shares) | shares	299,519
Warrants outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 5.62

Note 6 - Significant Alliance_2

Note 6 - Significant Alliances and Related Parties (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Research and Development Expense, Total	$ 118,258	$ 218,208
RPCI [Member]
Accounts Payable, Related Parties	0	1,197
The Cleveland Clinic [Member]
Research and Development Expense, Total	0	0
BBL [Member]
Research and Development Expense, Total	0	0
Accounts Receivable, Related Parties, Gross	0	6,285
Accounts Receivable, Related Parties	0	6,285
Incuron [Member]
Accounts Receivable, Related Parties, Gross	130,000	140,595
Accounts Receivable, Related Parties	0	140,595
Revenue from Related Parties	0	41,010
Sublease and Other Income, Related Parties	0	0
GPI [Member]
Sublease and Other Income, Related Parties	0	0
Related Party Transaction, Expenses from Transactions with Related Party	$ 13,440	$ 13,440